Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: shero who wrote (833)	12/9/1997 6:28:00 PM
From: EZLibra	Read Replies (1) \| Respond to of 3702

More like my-a culpa. Sorry, I also am still learning how to properly do copy and paste (I was so accomplished with a quotron!). I had to leave about noon and didn't quite understand the mystery until now. Still the point is that VTA/TNT is cytotoxic (kills primary tumors)while all them other guys are cytostatic (they shrink metastic tumors). I don't know if ENMD is the best of them other guys (SUGN and others may have something to say about it) but they have licensed half their antiangiogenesis arsenal to BMY with an option on the other half. This is my principal reasoning for conjecturing a BMY (Bristol-Myers-Squibb) license for VTA. You can see it's a very big license. It just figures. No word heard on China yet.